Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Key facts

Sponsor

OHSU Knight Cancer Institute

Principal Investigator

Kim-Hien Dao, DO, PhD

OHSU Knight Cancer Institute

Intervention

Laboratory Biomarker Analysis(other)

Enrollment

51 enrolled

Eligibility

18 years · All sexes

Timeline

2014 – 2020

Study locations (7)

• Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
• Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
• Washington University School of Medicine, St Louis, Missouri, United States
• OHSU Knight Cancer Institute, Portland, Oregon, United States
• UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
• M D Anderson Cancer Center, Houston, Texas, United States
• Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Atypical chronic myeloid leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07238712
  Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
  St. Petersburg State Pavlov Medical University
• RECRUITINGPHASE1, PHASE2NCT06523556
  Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
  Uma Borate
• RECRUITINGPHASE1NCT05549661
  Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
  Mayo Clinic

See all trials for Atypical chronic myeloid leukemia →